KALA BIO Inc.

KALA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.55

+$0.01 (+2.04%)

At close: Sep 21, 2026, 3:59 PM ET

$0.57

+$0.02 (+3.64%)

After-hours: Sep 21, 2026, 7:40 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Key Executives

Name	Position
Avi Minkowitz	CEO, CFO & Director
Carl Rennie	Executive Director of Account Management
Francis S. Mah	Chief Medical Advisor
Jill S. Steier	Executive Director of Investor Relations & Corporation Communications
Josiah Craver	Senior Vice President & Corporate Controller
Justin Hanes	Founder & Chair of the Scientific Advisory Board
Mary Reumuth	Treasurer & Secretary
Patrick Bedell	Executive Director of Trade & Alternate Channels
Vincent Kosewski	Senior Vice President of Manufacturing & Supply Chain Management

Latest SEC Filings

Date	Type	Title
Aug 28, 2026	8-K	Current Report
Aug 19, 2026	10-Q	Quarterly Report
Aug 14, 2026	NT 10-Q	Filing
Jul 23, 2026	8-K	Current Report
Jul 22, 2026	424B5	Filing
Jul 02, 2026	SC 13D/A	[Amend] Filing
Jun 25, 2026	EFFECT	Filing
Jun 12, 2026	S-3/A	[Amend] Filing
May 15, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
May 15, 2026	10-Q	Quarterly Report

View All SEC Filings ➞

KALA BIO Inc.

Country	United States
IPO Date	Jul 19, 2017
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Avi Minkowitz

Contact Details

1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States

https://www.kalarx.com

781 996 5252

Stock Details

Ticker Symbol	KALA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001479419
CUSIP Number	483119301
ISIN Number	US4831193010
SIC Code	2834